Skip to main content
. 2012 Sep;37(9):503-511, 530.

Table 5.

Immunotherapies Currently in Phase 3 Development for Advanced Melanoma

Company Product Type
Vical/AnGes MG Allovectin-7 Allogeneic, plasmid DNA/lipid complex
GlaxoSmithKline MAGE-A3 ASCI Allogeneic, peptide
Avax Technologies M-Vax Autologous, whole-cell, hapten-modified
Amgen (through acquisition of BioVex Group) T-VEC (formerly OncovexGM-CSF; talimogene laherparepvec) Allogeneic, oncolytic herpes simplex virus encoding GM–CSF

MAGE-A3 ASCI = mitogen-associated antigen A3 antigen-specific cancer immunotherapeutic; GM–CSF = granulocyte–macrophage colony-stimulating factor.

Data compiled from references 54 and 62 to 72.